Lowest hanging fruits were rebalance and CR to close into. I can't see them holding the position all the way through to a FDA decision on the back of strong data.
We know revenue will be after any type of raise event, but it's unknown how much impact certain catalyst will have tbh, or how long they'll take. Secure results will be more than a year away, so really it's P3 clarify/amplify and the coPSMA.
the out of left field is if AT decides to partner.
CU6 Price at posting:
$2.25 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)